24th Annual International Congress on the Future of Breast Cancer® East

Release Date: August 26, 2025

Expiration Date: August 26, 2026

Activity Overview

The 24th Annual International Congress on the Future of Breast Cancer^® East provides clinicians with cutting-edge updates on recent advances in the treatment of breast cancer, from preclinical breakthroughs to changes in clinical treatment paradigms. Novel agents and improved regimens, coupled with more in-depth molecular and phenotypic subtyping, are driving the future of breast cancer therapy. This dynamic program focuses on the practical implications of emerging data for patient care in the clinic. Recent data and their clinical impact are highlighted throughout the program, with expert perspectives on how to apply the evidence to individualize therapy for patients with breast cancer. Current areas of controversy or uncertainty are also debated, with discussion of ongoing clinical trials and investigational approaches designed to address these questions.

This conference provides a unique opportunity for medical, surgical, and radiation oncologists and other health care professionals to learn from and interact with international leaders in the field of breast cancer to increase knowledge, apply new data to practice, and, ultimately, improve patient outcomes.

This educational activity is an archive of the live presentation held on July 11-12, 2025.

For more information about this educational activity, the faculty, and disclosures, please click here.

Target Audience

This educational activity is intended for medical, surgical, and radiation oncologists involved in the treatment of patients with breast cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of breast cancer may also participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Explain the utility of genomic and molecular biomarker assays in supporting individualized treatment selection in early-stage and metastatic breast cancer settings.
• Identify opportunities for multidisciplinary care coordination to optimize surgical and radiation strategies to maintain locoregional control in patients with breast cancer.
• Apply efficacy and safety data from pivotal clinical trials to optimize treatment plans for patients with early-stage and advanced/metastatic breast cancer.
• Examine investigational therapies for the treatment of breast cancer and the potential place of novel agents within evolving treatment paradigms and guidelines.
• Determine strategies for the prevention and/or management of adverse events associated with treatments for breast cancer.

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource^®, LLC (PER^®) have no relevant financial relationships with ineligible companies.

PER mitigated all COI for faculty, staff, and planners prior to the start of this activity.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER or any company that provided commercial support for this activity.